A comparison of continuous glucose monitors (CGMs) in diabetes management: A systematic literature review

Centers for Disease Control and Prevention. National Diabetes Statistics Report website. 〈https://www.cdc.gov/diabetes/data/statistics-report/index.html〉. Accessed October 1,2022. Michael Yapanis, 2022, Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring, J. Clin. Endocrinol. Metab., Volume 107, e2221, 10.1210/clinem/dgac034 Deshpande, 2008, Epidemiology of diabetes and diabetes-related complications, Phys. Ther., 88, 1254, 10.2522/ptj.20080020 Ehrhardt, 2019, Behavior modification in prediabetes and diabetes: potential use of real-time continuous glucose monitoring, J. Diabetes Sci. Technol., 13, 271, 10.1177/1932296818790994 Laffel L.M., Kanapka L.G., Beck R.W., Bergamo K., Clements M.A., Criego A., DeSalvo D.J., Goland R., Hood K., Liljenquist D., Messer L.H., Monzavi R., Mouse T.J., Prahalad P., Sherr J., Simmons J.H., Wadwa R.P., Weinstock R.S., Willi S.M., Miller K.M.; CGM Intervention in Teens and Young Adults with T1D (CITY) Study Group; CDE10. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020 Jun 16;323(23):2388–2396. doi: 10.1001/jama.2020.6940. PMID: 32543683; PMCID: PMC7298603. ADA. 〈https://diabetes.org/diabetes/a1c/diagnosis〉. Accessed October 10, 2022. Xu, 2018, Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study, BMJ, 362, k1497, 10.1136/bmj.k1497 Sanai F., Sahid A.S., Huvanandana J., et al. Evaluation of a Continuous Blood Glucose Monitor: A Novel and Non-Invasive Wearable Using Bioimpedance Technology. Journal of Diabetes Science and Technology. 2021;0(0). doi:10.1177/19322968211054110. Olczuk, 2018, A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus, Diabetes Metab. Syndr., 12, 181, 10.1016/j.dsx.2017.09.005 Diabetes history > defeat diabetes foundation. Defeat Diabetes Foundation. 〈https://defeatdiabetes.org/diabetes-history/〉. Published July 24, 2018. Accessed December 1, 2022. The history of diabetes. TheDiabetesCouncil.com. 〈https://www.thediabetescouncil.com/the-history-of-diabetes/〉. Published December 27, 2019. Accessed December 1, 2022. Tang, 2020, Non-invasive blood glucose monitoring technology: a review, Sensors, 20, 6925, 10.3390/s20236925 Garg, 2022, Accuracy and safety of dexcom G7 continuous glucose monitoring in adults with diabetes, Diabetes Technol. Ther., 24, 373, 10.1089/dia.2022.0011 Medtronic. (n.d.). Diabetes - guardian™ connect system. Medtronic. Retrieved February 1, 2023, from 〈https://www.medtronic.com/us-en/healthcare-professionals/products/diabetes/continuous-glucose-monitoring-systems/guardian-connect.html〉. Joseph, 2021, Review of the long-term implantable senseonics continuous glucose monitoring system and other continuous glucose monitoring systems, J. Diabetes Sci. Technol., 15, 167, 10.1177/1932296820911919 Premarket approval (PMA). accessdata.fda.gov. (n.d.). Retrieved February 16, 2023, from 〈https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980022〉. Dillmann, 2022, Feasibility of real-time continuous glucose monitoring telemetry system in an inpatient diabetes unit: a pilot study, J. Diabetes Sci. Technol., 16, 955, 10.1177/1932296821994586 Ruedy, 2017, Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial, J. Diabetes Sci. Technol., 11, 1138, 10.1177/1932296817704445 Ravi, 2021, Pediatric medicaid patients with type 1 diabetes benefit from continuous glucose monitor technology, J. Diabetes Sci. Technol., 15, 630, 10.1177/1932296820906214 Davis, 2021, Accuracy of dexcom G6 continuous glucose monitoring in non-critically Ill hospitalized patients with diabetes, Diabetes Care, 44, 1641, 10.2337/dc20-2856 Al Hayek, 2021, Impact of the FreeStyle Libre flash glucose monitoring system on diabetes- self-management practices and glycemic control among patients with type 2 diabetes in Saudi Arabia: a prospective study, Diabetes Metab. Syndr., 15, 557, 10.1016/j.dsx.2021.02.027 Fokkert, 2019, Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4), BMJ Open Diabetes Res. Care, 7, 10.1136/bmjdrc-2019-000809 Alva, 2022, Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes, J. Diabetes Sci. Technol., 16, 70, 10.1177/1932296820958754 Al Hayek, 2021, Effectiveness of the freestyle libre 2 flash glucose monitoring system on diabetes-self-management practices and glycemic parameters among patients with type 1 diabetes using insulin pump, Diabetes Metab. Syndr., 15, 10.1016/j.dsx.2021.102265 Al Hayek, 2021, Frequency of diabetic ketoacidosis in patients with type 1 diabetes using freestyle libre: a retrospective chart review, Adv. Ther., 38, 3314, 10.1007/s12325-021-01765-z Ajjan, 2019, Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: a pilot, multicentre, randomised controlled trial, Diabetes Vasc. Dis. Res., 16, 385, 10.1177/1479164119827456 Christiansen, 2019, A prospective multicenter evaluation of the accuracy and safety of an implanted continuous glucose sensor: the PRECISION study, Diabetes Technol. Ther., 21, 231, 10.1089/dia.2019.0020 Irace, 2020, Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes, Diabetes Obes. Metab., 22, 1056, 10.1111/dom.13993 Avari, 2020, Glycemic variability and hypoglycemic excursions with continuous glucose monitoring compared to intermittently scanned continuous glucose monitoring in adults with highest risk type 1 diabetes, J. Diabetes Sci. Technol., 14, 567, 10.1177/1932296819867688 Boscari, 2018, FreeStyle libre and dexcom G4 platinum sensors: accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions, Nutr., Metab., Cardiovasc. Dis.: NMCD, 28, 180, 10.1016/j.numecd.2017.10.023 Reddy, 2018, A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia, Diabet. Med.: a J. Br. Diabet. Assoc., 35, 483, 10.1111/dme.13561 Hásková, 2020, Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial, Diabetes Care, 43, 2744, 10.2337/dc20-0112 Sadhu, 2020, Continuous glucose monitoring in critically Ill patients with COVID-19: results of an emergent pilot study, J. Diabetes Sci. Technol., 14, 1065, 10.1177/1932296820964264 Fokkert, 2020, Performance of the eversense versus the free style libre flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus, BMJ Open Diabetes Res. Care, 8, 10.1136/bmjdrc-2020-001193 Christiana T. Somorin PDCFAMUCof Pand PST. IPro2 continuous glucose monitoring system. U.S. Pharmacist – The Leading Journal in Pharmacy. 〈https://www.uspharmacist.com/article/ipro2-continuous-glucose-monitoring-system〉. Published May 18, 2018. Accessed April 28, 2023. Medtronic. Diabetes treatment - ipro2 professional CGM. Medtronic. 〈https://www.medtronic.com/ca-en/diabetes/home/products/cgm-systems/ipro2-professional.html〉. Accessed April 28, 2023. ANON. Premarket approval (PMA). accessdata.fda.gov. 〈https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980022S200〉. Accessed April 28, 2023. Continuous glucose monitors (CGM) L danatech. ADCES. (n.d.). Retrieved April 17, 2023, from 〈https://www.diabeteseducator.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)〉. Center for Devices and Radiological Health. (n.d.). Eversense E3 continuous glucose monitoring system - P160048/S016. U.S. Food and Drug Administration. Retrieved April 17, 2023, from 〈https://www.fda.gov/medical-devices/eversense-e3-continuous-glucose-monitoring-system-p160048s016〉. 510(k) premarket notification. accessdata.fda.gov. (n.d.). Retrieved April 17, 2023, from 〈https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm〉.